PTC Therapeutics PTCT Business Segments — Depreciation

Similar metrics at other companies

RVTYLife Sciences — Depreciation

$9.91M+37.9%

BIOLife Science — Depreciation, Depletion and Amortization

$18.3M+7.6%

DHRLife Sciences — Depreciation

$48M+6.7%

TMOLife Sciences Solutions — Depreciation of property, plant and equipment

$70M+18.6%

ALife Sciences and Diagnostics Markets — Depreciation

$26M+8.3%

GLW

GLWLife Sciences and Emerging Growth Businesses — Depreciation

$26M-10.3%

Questions, answered.

What is PTC Therapeutics's business segments — depreciation?

PTC Therapeutics (PTCT) reported business segments — depreciation of $3.81M in Q1 2026.

How has PTC Therapeutics's business segments — depreciation changed year-over-year?

PTC Therapeutics's business segments — depreciation increased by 10.1% year-over-year, from $3.46M to $3.81M.

What is the long-term trend for PTC Therapeutics's business segments — depreciation?

Over 2 years (2023 to 2025), PTC Therapeutics's business segments — depreciation has grown at a 0.9% compound annual growth rate (CAGR), from $13.95M to $14.2M.

What does business segments — depreciation mean?

This metric represents the systematic allocation of the cost of tangible assets over their useful lives within the Life Science segment. It is a non-cash expense that reflects the wear and tear or obsolescence of physical infrastructure, such as laboratory equipment and facilities. Tracking this metric is essential for understanding the segment's capital intensity and the ongoing reinvestment required to maintain operational capacity.